NewGenIvf Group Limited
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Wing Fung Siu
- Full Time Employees
- 87
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- PS Tower, 36/39-36/40, 13th Floor Bangkok BM Thailand 10110
- IPO Date
- Mar 18, 2022
- CIK
- 0001981662
- Website
- nivf.global
- Similar Companies
- Business
- NewGenIvf Group Limited operates as a diversified healthcare and investment holding company primarily engaged in assisted reproductive services across the Asia-Pacific region. The company provides a comprehensive range of fertility treatment solutions including in vitro fertilization (IVF) comprising traditional IVF and egg donation; intracytoplasmic sperm injection (ICSI); embryo culture; hormonal blood tests; infectious disease screenings; chromosome screening; hysteroscopy; sperm analysis, sorting, washing, and freezing; and egg freezing. Ancillary services include surrogacy arrangements with related caregiving such as regular health checks, nutritional supplements, vitamins, medicines for surrogate mothers, psychological counseling, acupuncture, nutrition guidance, and translation services. The company delivers its services through a network of clinics located in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. Founded in 2010, NewGenIvf is headquartered in Bangkok, Thailand. In the last two years, NewGenIvf has undergone a major strategic transformation transitioning from its traditional fertility service model to a technology-driven platform emphasizing licensing, royalties, and sales of proprietary consumables. This shift is anchored by its acquisition of advanced cytometry technology, including 18 fully constructed cell-sorting systems, partially completed units, and six patents related to microfluidic systems to enhance its proprietary NewGenSort sperm cell separation service. This technology supports precise X and Y chromosome sperm sorting for IVF procedures, aimed at capturing a portion of the U.S. fertility market. The company projects this technology to facilitate over 25,000 sorts annually with anticipated gross revenues exceeding $20 million from the U.S. market upon full operational rollout by early 2026. Additionally, NewGenIvf is expanding its business scope through strategic investments outside traditional fertility services, including a $45 million investment in UAE real estate development focused near the Wynn Al Marjan Island resort and ventures into digital asset management such as tokenization and blockchain treasury strategies targeting sustainable growth. The company reported a significant bargain purchase gain exceeding $23 million linked to its recent acquisitions and intellectual property valued at approximately $17.9 million, which enhances its net asset value and profitability outlook. NewGenIvf's evolving business model leverages cutting-edge reproductive technology, digital assets, and real estate ventures to build a diversified, high-growth portfolio underpinned by licensing and royalty-based revenue streams. This dual-engine strategy positions the company to deliver innovative fertility solutions and broader wealth generation initiatives. The company trades publicly under the ticker NIVF and remains headquartered in Bangkok, Thailand, maintaining a strong presence throughout Asia and expanding into the U.S. market via technology deployment and acquisitions.
Company News
NewGenIVF Completes Exchange of Convertible Notes with Institutional Investor
NewGen Provides Update on K25.ai Investment and Strengthened Financial Position
NewGen to Acquire Additional 3% of K25.ai at US$250 Million Valuation Following Strong Community Beta; Strengthening Market Cap Above US$5 Million
NewGen's Strategic Pre-A Investment in K25.ai Doubles in Value as K25.ai's Valuation Reaches US$200 Million
K25.ai Secures Series A Investment with Strategic Support from Amber Group, Valuation Doubles to US$200 Million
NewGen's Advanced Cytometry Platform Poised for Major UAE/GCC Expansion with Big Four Valuation of US$19 Million
NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization
NewGen Increases K25.ai Ownership to 10% in Closed Pre-A Round at US$100 Million Valuation with Total US$10 Million Invested
NewGen Increases K25.ai Ownership to 10% in Closed Pre-A Round at US$100 Million Valuation with Total US$10 Million Invested
NewGen Eliminates Convertible Note and Warrant Overhang with a Significant Investor, Enters Into Settlement Agreement Strengthening Capital Structure
NewGen Doubles Down on K25.ai with Additional US$4 Million Stake and Adopts Digital Asset Treasury Strategy
NewGen Executes Share Purchase Agreement and Obtains Exclusive APAC Agency Rights with K25.ai, an AI-Powered Prediction Market Led by Industry Veteran Andy Cheung
K25.ai, Led by Tech Veteran Andy Cheung, Eyes Public Listing as World's First Prediction Market After $100M Valuation Investment from Nasdaq-Listed Strategic Partner
NewGenIVF Announces Strategic Investment Agreement with Tech Veteran Andy Cheung-Led K25.ai, an AI-Powered Live-Streaming Prediction Market, at US$100 Million Valuation
NewGen Provides Update on Fiscal Year 2025 Results and Strategic Progress
Contrasting NewGenIvf Group (NASDAQ:NIVF) and BrightSpring Health Services (NASDAQ:BTSG)
NewGenIvf Group Limited (NASDAQ:NIVF) Short Interest Up 80.4% in February
NewGen and Evident Capital Successfully Activate Commitment Campaign for Inaugural Tokenized Real Estate Bond, Delivering on Cross-Border Real World Asset Financing Strategy
NewGen to Execute Up to US$2 Million Share Repurchase Program Through Benchmark
NewGenIvf Group (NASDAQ:NIVF) Shares Scheduled to Reverse Split on Monday, January 26th